Immunohistochemistry firm Biocare Medical and Proteintech, a developer and manufacturer of antibodies and proteins for life science research, have announced a strategic collaboration and to advance next-generation antibody solutions supporting modern pathology workflows.
The collaboration combines Proteintech's advanced antibody discovery and protein engineering capabilities with Biocare's expertise in diagnostic immunohistochemistry, assay validation, and pathology laboratory workflows. By leveraging Proteintech's ABCE platform, which integrates scalable antibody design and development processes, the companies aim to accelerate the development of high-performance antibody reagents designed to support tissue-based diagnostics, translational research, and emerging biomarker-driven applications in precision oncology.
"Pathology laboratories are under increasing pressure to deliver accurate results while managing growing case volumes and persistent workforce shortages," said Luis de Luzuriaga, CEO at Biocare Medical. "By combining Proteintech's advanced antibody engineering capabilities with Biocare's diagnostic validation expertise, this collaboration strengthens our ability to deliver digital-ready reagents that support reliable, reproducible assays across modern pathology workflows."
The collaboration also reflects broader industry efforts to address longstanding challenges related to antibody reproducibility and assay standardisation across both research and diagnostic applications. Biocare has developed one of the industry's most specialised immunohistochemistry portfolios, including more than 300 IVD antibodies designed for multi-platform compatibility, enabling laboratories to standardise staining performance across diverse instrument environments. Proteintech's expertise in antibody production builds on that foundation by expanding the development of antibodies engineered to support reproducible tissue-based assays and evolving digital pathology workflows.
Beyond digital-ready diagnostic workflows, this collaboration also supports growing demand for tissue-based biomarkers in precision oncology, including applications related to antibody–drug conjugates (ADCs) and companion diagnostics, as well as emerging spatial biology technologies. As these technologies increasingly move toward standardised translational and clinical applications, their widespread adoption will require the IVD-grade antibodies, assay standardisation, and rigorous quality control long established in immunohistochemistry.